Human Exploration and Operations Committee Status Committee Chair - Ken Bowersox August 29, 2018 NAC HEO Committee Members – August, 2018 • Ms. Bartell, Shannon • Mr. Bowersox, Ken, Chair • Ms. Budden, Nancy Ann • Ms. Caserta Gardner, Ruth G. • Dr. Chiao, Leroy • Dr. Condon, Stephen "Pat" • Mr. Cuzzupoli, Joseph W. • Mr. Holloway, Tom • Mr. Lon Levin • Dr. Longenecker, David E. • Mr. Lopez-Alegria, Michael • Mr. McDaniel, Mark • Mr. Sieck, Robert • Mr. Voss, James 2 NAC HEO Meeting Summary August, 2018 NAC HEO Committee Meeting Monday, August 27, 2018 Human Exploration & Operations Status Commercial Crew Program Status Exploration Systems Status Gateway Power Propulsion Element Status International Space Station Status Tuesday August 28, 2018 Joint Meeting with Science Committee SMD HEOMD Cislunar Activities Overview Gateway Overview Cislunar and Surface Science Transformative Lunar Science Tour of Ames Research Center 3 54S Dock 3/23/18 55S Dock 6/8/18 54S Undock 10/4/18 Drew Feustel Alexander Gerst 55S Undock 12/13/18 FE (US) – 54S FE (E) – 55S (CDR Inc 56) (CDR Inc 57) Sergey Prokopyev Oleg Artemyev Soyuz CDR (R) – 55S Soyuz CDR (R) – 54S Ricky Arnold Serena Auñón-Chancellor FE (US) – 54S FE (US) – 55S 9/4/18 4 Pre-Decisional, For Internal NASA Use Only } Increment 56: 123 days ◦ Stage 56-3: 53S undock to 55S dock: 5 days ◦ Stage 56-6: 55S dock to 54S undock: 118 days ◦ EVAs US EVA (6/14) N2 Fwd EWC, CP3 EHDC, CATS Aperture Door RS EVA (8/15) Satellite deploy, cable & antenna install US EVA (9/23) P4 Battery R&R – 4A (HTV- 7 EVA1) US EVA (10/1) P4 Battery R&R – 2A (HTV- 7 EVA2) ◦ Visiting vehicles: Progress 70P (Dock 7/10) Progress 69P (Undock 8/29) SpX-15 (Berth 7/2, Unberth 8/2) OA-9 (Unberth 7/15) HTV7 (Berth 9/15, Unberth 11/14) ◦ Science/Utilization: Augmented Utilization Hours RR7 ◦ Maintenance/Outfitting: UIA R&R (June) Upgraded Airlock Umbilical Interface Assy Rack Relocations/Prep Work for HTV-7 LEE FSE Install/Return ◦ Other: Arcturus Deploy EMU EVA Data Recorder Installation 9/4/18 5 Pre-Decisional, For Internal NASA Use Only • First integrated 3D Printer and Recycler (terrestrially or in space) • The Refabricator will demonstrates the process of manufacturing parts, recycling them back into useable filament, and ‘printing’ new parts from the recycled feedstock – The technology demonstration includes a minimum of seven closed loop recycling/fabricating cycles with a goal of up to fourteen cycles. – Filament feedstock produced during each recycling process will be used to 3D print multiple tensile specimen and a plastic input block to be used in the next recycling process – Due to the patented extrusion process which doesn’t require any grinding process like that traditionally used for recycling, little-to-no material degradation has been observed in the printed parts after multiple recycles in ground testing. The flight specimen will be returned for analyses and testing to determine what, if any, material degradation resulted from multiple Refabricator Tech Demo and Ops Timeline recycles in microgravity. 5/18 11/18 12/18 5/19 • The payload is remotely operated from the ground with internal cameras for viewing the fabrication and recycling process real-time. The only required crew operation is for the crew to H/W NG-10 ISS Initial Demo remove the parts and re-load the input block once each cycle, which can be task listed. Delivery Launch Install Complete • Sponsored by HEOMD AES and STMD GCD Note: Dates for ISS operations are • Refabricator hardware development heavily leveraged the Small Business Innovative Research estimates and may vary based on (SBIR) program via Phase I, II, II-E, and III SBIR awards to Tethers Unlimited, Inc. (TUI). available ISS resources and priorities. • Flight hardware has been turned with launch anticipated on NG-10 in November 2018 6 Research Summary • Launched on SpX-15, this investigation examines whether endothelial cells, cultured in microgravity represent a valid in vitro model to test effects of vascular-targeted agents on normal blood vessels. • Angiex has developed a treatment that targets both tumor cells and vasculature, but needs a better model on which to test it. • The study may facilitate a cost-effective method that does not require animal testing and Endothelial cells produce high levels of TM4SF1 (green) in which may help develop safer and more effective vascular-targeted drugs. order to engage in movement, proliferation, and intercellular interactions. [Image courtesy of Angiex] Angiex’s anti-TM4SF1 cancer drug effectively regresses human tumors Structure of Tetraspanins. [From Yang, Y.-G. et al., implanted into the flank of nude mice. [Image courtesy of Angiex] Angiogenesis in Cancer. [From Sigma-Aldrich / Experimental Hematology 2016, 44:322-328] Millipore-Sigma, Angiogenesis Assays] 7 HRP Integrated Path to Risk Reduction, Revision E PPBE20 Baseline 5/18/18 Mars Flyby FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 FY27 FY28 FY29 FY30 ISS Risks LxC EM-1 EM-2 EM-3 EM-4 EM-5 EM-6 EM-7 EM-8 EM-9 End Space Radiation Exposure - Cancer 3x4 Space Radiation Exposure - Degen 3x4 Space Radiation Exposure - Integrated CNS 3x4 Cognitive or Behavioral Conditions (BMed) 3x4 Inadequate Food and Nutrition (Food) 3x4 Team Performance DeCrements (Team) 3x4 SpaCeflight AssoCiated Neuro-Ocular Syndrome (SANS/VIIP) 3x4 Renal Stone Formation (Renal) 3x4 Human-System InteraCtion Design (HSID) 3x4 MediCations Long Term Storage (Stability) 2x4 Inflight MediCal Conditions (MediCal) 3x4 Injury from DynamiC Loads (OP) 3x3 Injury Due to EVA Operations (EVA) 3x3 HypobariC Hypoxia (ExAtm) 3x3 DeCompression SiCkness (DCS) 3x2 Altered Immune Response (Immune) 3x3 Host-MiCroorganism InteraCtions (MiCrohost) 3x3 Sensorimotor Alterations (SM) 3x3 Reduced Muscle Mass, Strength (Muscle) 3x3 Reduced AerobiC Capacity (AerobiC) 3x3 Sleep Loss and Circadian Misalignment (Sleep) 3x3 OrthostatiC Intolerance (OI) 3x2 Bone FraCture (FraCture) 1x4 CardiaC Rhythm Problems (Arrhythmia) 3x2 Space Radiation Exposure - ACute Radiation SPE 2x2 Concern of Intervertebral DisC Damage (IVD) TBD Celestial Dust Exposure (Dust) TBD Concern of EffeCts of MediCation (PK/PD) TBD ISS End ISS Required Milestone Requires ISS ISS Mission Milestone - Anticipated Milestone Shift 18 May 2018 ISS Not Required Ground-based Milestone Exploration Mission Milestone 8 High LxC Mid LxC: Requires Mid LxC: Accepted Low LxC Optimized Insufficient Data Mitigation 8 } Commercial: IBM, Sanofi Pasteur, Lockheed Martin, Harris } Also National Cancer Institute, Frederick ISS Cotton National Lab, Caltech, Stanford, Clemson Sustainability } New partnerships formalized with Challenge Bigelow, Axiom, and Sierra Nevada } Target Corp. completed the first fully funded commercial Sponsored Program } A CASIS-hosted Implementation Partner Portal has been operational since April and has 40+ active registered users } A CASIS-hosted Investment Portal is also now live 9 } 3 patent applications from P&G were published as a result of ISS National Lab R&D, related to product development and shelf life } A patent application was published related to ZBLAN production on the ISS by Fiber Optics Manufacturing in Space } Made in Space completed 1st demo for ZBLAN manufacturing in space } In June, Apple (#4 on Fortune’s 500) previewed new aerial images of Earth, taken from the ISS (expected release Fall 2018) } 12 new academic journal articles from CASIS-sponsored R&D ◦ Mostly cell culture & rodent research, with one student-authored paper ◦ A special issue of Stem Cells and Development also highlighted results from ISS National Lab investigations 10 } NASA released a NASA Research Announcement (NRA) to solicit proposals for study activities related to the development of a LEO commercial market where NASA could be one of many customers ◦ Released on May 17, 2018 ◦ Received proposals on June 18, 2018 ◦ Selected companies announced on August 8, 2018 (contracts are dependent on negotiations) ◦ Final study reports delivered to NASA in December 2018 11 Ø The following study selections were announced on August 8, 2018 • AxiomSpace, LLC, of Houston • Blue Origin, LLC, of Kent, Washington • The Boeing Company of Houston • Deloitte Consulting of Manhattan Beach, California • KBRWyle of Houston • Lockheed Martin Corporation of Littleton, Colorado • McKinsey & Company, Inc. of Washington, D.C. • NanoRacks, LLC, of Webster, Texas • Northrop Grumman of Dulles, Virginia • Sierra Nevada Corp. of Louisville, Colorado • Space Adventures, Inc., of Vienna, Virginia • Space Systems/Loral, Inc. of Palo Alto, California 12 Ø Working to expand on description of NASA needs in the ISS Transition Report and facilities/features required of a LEO platform to support it ◦ Regular crewed operations ◦ Long-term technology and system demonstrations ◦ Human health performance and validation ◦ Space Life and Physical Sciences Research ◦ Astrophysics, Space and Earth Science 13 Orion Spacecraft Status Space Launch System (SLS) Status Exploration Ground Systems Status 19 Summary ! CCP continues to facilitate the development and certification of U.S. industry-based Crew Transportation Systems ! Boeing and SpaceX are meeting contractual milestones and maturing their designs – A significant amount of hardware is in development, test, and qualification in preparation for upcoming missions – Risks are being identified and important design challenges are being addressed – NASA is engaged in meaningful insight Boeing CST-100 Starliner ! Both providers are making tangible progress toward